Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Influenza

Free Subscription Articles published in Drug Saf Retrieve available abstracts of 47 articles: HTML format

Single Articles

May 2024
1. CAPLANUSI I, Szmigiel A, van der Elst M, Schougaard Christiansen ML, et al
   The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally.
   Drug Saf. 2024;47:405-418.
   PubMed     Abstract available
   
   
   March 2024
2. DOS SANTOS G, Devadiga R, Kim CS, Bang J, et al
   An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged
   Drug Saf. 2024 Mar 14. doi: 10.1007/s40264-024-01395.
   PubMed     Abstract available
   
   
   
3. WYSZYNSKI DF, Papageorghiou AT, Renz C, Metz TD, et al
   The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations.
   Drug Saf. 2024;47:195-204.
   PubMed     Abstract available
   
   
   February 2024
4. MORO PL, Ennulat C, Brown H, Woody G, et al
   Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
   Drug Saf. 2024 Feb 27. doi: 10.1007/s40264-024-01406.
   PubMed     Abstract available
   
   
   
5. QIN SX, Cheng FWT, Kwok WC, Fung LWY, et al
   Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.
   Drug Saf. 2024;47:135-146.
   PubMed     Abstract available
   
   
   
6. DONG G, Bate A, Haguinet F, Westman G, et al
   Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
   Drug Saf. 2024;47:173-182.
   PubMed     Abstract available
   
   
   December 2023
7. DE GERMAY S, Singier A, Salvo F, Pariente A, et al
   Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
   Drug Saf. 2023;46:1381-1389.
   PubMed     Abstract available
   
   
   November 2023
8. MICALLEF B, Dogne JM, Sultana J, Straus SMJM, et al
   An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance.
   Drug Saf. 2023;46:1089-1103.
   PubMed     Abstract available
   
   
   October 2023
9. SLINGERLAND P, van Hunsel FPAM, Lieber T, van Balveren L, et al
   The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands.
   Drug Saf. 2023 Oct 26. doi: 10.1007/s40264-023-01356.
   PubMed     Abstract available
   
   
   September 2023
10. WALTON M, Pletzer V, Teunissen T, Lumley T, et al
    Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
    Drug Saf. 2023;46:867-879.
    PubMed     Abstract available
    
    
    June 2023
11. KAUR U, Fatima Z, Maheshwari K, Sahni V, et al
    Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
    Drug Saf. 2023;46:553-563.
    PubMed     Abstract available
    
    
    
12. AHMADIZAR F, Luxi N, Raethke M, Schmikli S, et al
    Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.
    Drug Saf. 2023;46:575-585.
    PubMed     Abstract available
    
    
    May 2023
13. KRALOVA K, Wilson CA, Richebourg N, D'souza J, et al
    Quality of MedDRA((R)) Coding in a Sample of COVID-19 Vaccine Medication Error Data.
    Drug Saf. 2023;46:501-507.
    PubMed     Abstract available
    
    
    April 2023
14. BAUCHAU V, Davis K, Frise S, Jouquelet-Royer C, et al
    Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities.
    Drug Saf. 2023;46:327-333.
    PubMed     Abstract available
    
    
    
15. RAETHKE M, van Hunsel F, Thurin NH, Dureau-Pournin C, et al
    Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Drug Saf. 2023;46:391-404.
    PubMed     Abstract available
    
    
    
16. OGAR CK, Quick J, Gilbert HN, Vreman RA, et al
    Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
    Drug Saf. 2023;46:357-370.
    PubMed     Abstract available
    
    
    March 2023
17. KALKNER KM, Sundstrom A, Nurminen ML, Larsson M, et al
    Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency.
    Drug Saf. 2023;46:319-321.
    PubMed    
    
    
    
18. WYSZYNSKI DF, Bhattacharya M, Martinez-Perez O, Scialli AR, et al
    The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations.
    Drug Saf. 2023;46:297-308.
    PubMed     Abstract available
    
    
    
19. ZAPATA-CACHAFEIRO M, Prieto-Campo A, Portela-Romero M, Carracedo-Martinez E, et al
    Effect of Previous Anticoagulant Treatment on Risk of COVID-19.
    Drug Saf. 2023;46:273-281.
    PubMed     Abstract available
    
    
    February 2023
20. DIAK IL, Swank K, McCartan K, Beganovic M, et al
    The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic.
    Drug Saf. 2023;46:145-155.
    PubMed     Abstract available
    
    
    January 2023
21. OOSTERHUIS I, Scholl J, van Puijenbroek E, Kant A, et al
    Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.
    Drug Saf. 2023;46:65-75.
    PubMed     Abstract available
    
    
    December 2022
22. WAN EYF, Chui CSL, Mok AHY, Xu W, et al
    mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study.
    Drug Saf. 2022;45:1477-1490.
    PubMed     Abstract available
    
    
    October 2022
23. KAUR U, K L A, Chauhan M, Joshi A, et al
    A Prospective Observational Study on BBV152 Coronavirus Vaccine Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis.
    Drug Saf. 2022;45:1099-1109.
    PubMed     Abstract available
    
    
    September 2022
24. LANE S, Shakir S
    Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.
    Drug Saf. 2022;45:1003-1008.
    PubMed     Abstract available
    
    
    August 2022
25. KANT A, van Hunsel F
    Authors' Reply to Mungmunpuntipantip et al.'s Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands".
    Drug Saf. 2022;45:925-926.
    PubMed    
    
    
    
26. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands".
    Drug Saf. 2022;45:923.
    PubMed    
    
    
    July 2022
27. HARPAZ R, DuMouchel W, Van Manen R, Nip A, et al
    Signaling COVID-19 Vaccine Adverse Events.
    Drug Saf. 2022;45:765-780.
    PubMed     Abstract available
    
    
    June 2022
28. SHOAIBI A, Rao GA, Voss EA, Ostropolets A, et al
    Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.
    Drug Saf. 2022;45:685-698.
    PubMed     Abstract available
    
    
    May 2022
29. MARTIN GL, Jouganous J, Savidan R, Bellec A, et al
    Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
    Drug Saf. 2022;45:535-548.
    PubMed     Abstract available
    
    
    April 2022
30. KANT A, Jansen J, van Balveren L, van Hunsel F, et al
    Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Drug Saf. 2022;45:319-331.
    PubMed     Abstract available
    
    
    February 2022
31. FERNER RE, Stevens RJ, Anton C, Aronson JK, et al
    Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity.
    Drug Saf. 2022;45:137-144.
    PubMed     Abstract available
    
    
    December 2021
32. LUXI N, Giovanazzi A, Capuano A, Crisafulli S, et al
    COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
    Drug Saf. 2021;44:1247-1269.
    PubMed     Abstract available
    
    
    November 2021
33. CLINTON JW, Kiparizoska S, Aggarwal S, Woo S, et al
    Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.
    Drug Saf. 2021;44:1125-1149.
    PubMed     Abstract available
    
    
    
34. IGUCHI T, Umeda H, Kojima M, Kanno Y, et al
    Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Drug Saf. 2021;44:1209-1214.
    PubMed     Abstract available
    
    
    October 2021
35. SALAMANCA DE LA CUEVA I, Cinconze E, Eckermann T, Nwoji U, et al
    Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Drug Saf. 2021 Oct 25. pii: 10.1007/s40264-021-01121.
    PubMed     Abstract available
    
    
    September 2021
36. ROCCA E, Gauffin O, Savage R, Vidlin SH, et al
    Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Drug Saf. 2021;44:987-998.
    PubMed     Abstract available
    
    
    
37. MOORE N, Bosco-Levy P, Thurin N, Blin P, et al
    NSAIDs and COVID-19: A Systematic Review and Meta-analysis.
    Drug Saf. 2021;44:929-938.
    PubMed     Abstract available
    
    
    June 2021
38. BHOWMICK S, Dang A, Vallish BN, Dang S, et al
    Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
    Drug Saf. 2021;44:635-644.
    PubMed     Abstract available
    
    
    April 2021
39. DASGUPTA N
    Safety Consequences of Off-Label Drugs Used for COVID-19.
    Drug Saf. 2021;44:399-402.
    PubMed    
    
    
    
40. GRANDVUILLEMIN A, Drici MD, Jonville-Bera AP, Micallef J, et al
    French Pharmacovigilance Public System and COVID-19 Pandemic.
    Drug Saf. 2021;44:405-408.
    PubMed     Abstract available
    
    
    February 2021
41. MARZOLINI C, Stader F, Leuppi-Taegtmeyer A, Stoeckle M, et al
    Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
    Drug Saf. 2021;44:255-257.
    PubMed    
    
    
    January 2021
42. BEYZAROV E, Chen Y, Julg R, Naim K, et al
    Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
    Drug Saf. 2021;44:95-105.
    PubMed     Abstract available
    
    
    
43. SHAKIR S, Lane S, Davies M
    How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
    Drug Saf. 2021;44:1-5.
    PubMed    
    
    
    December 2020
44. GARCIA P, Revet A, Yrondi A, Rousseau V, et al
    Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Drug Saf. 2020;43:1315-1322.
    PubMed     Abstract available
    
    
    
45. PETOUSIS-HARRIS H
    Assessing the Safety of COVID-19 Vaccines: A Primer.
    Drug Saf. 2020;43:1205-1210.
    PubMed     Abstract available
    
    
    
46. ZEKARIAS A, Watson S, Vidlin SH, Grundmark B, et al
    Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Drug Saf. 2020;43:1309-1314.
    PubMed     Abstract available
    
    
    
47. TRIFIRO G, Massari M, Da Cas R, Menniti Ippolito F, et al
    Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Drug Saf. 2020;43:1297-1308.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.